Combination Therapies 2 : Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases

The 2nd International Symposium on Combination Therapies brought together several hundred of the leading researchers, scientists and clinicians in this area to discuss new and emerging uses for biological response modifiers (BRM's) in the treatment of cancer and infectious diseases. The meeting was held during May 1-3, 1992 in Acireale, Sicily (Italy). It was hosted by Professor G. Nicoletti CU. of Catania) and organized by the Institute for Advanced Studies in Immunology and Aging (Washington, D. C. ) in collaboration with the University of Rome "Tor Vergata," the University of Catania and The George Washington University Medical Center. The synergy exhibited between BRM's and conventional therapies including bone marrow and other lymphoid cell transplants is a rapidly expanding area with significant promise for the treatment of human diseases. Advances in this area of biomedicine are leading to the rapid development of new therapeutic approaches that are being applied clinically as both primary and adjuvant therapy to enhance the effectiveness of conventional treatments. The 2nd International Symposium on Combination Therapy provided a setting for the exchange of new scientific information regarding the emerging uses for BRM's alone or in combination with conventional therapies. The 1st International Symposium on Combination Therapies was held in 1991 in Washington, D. C. Front Matter....Pages i-x Cytokine Synergy in Immunotherapy....Pages 1-10 Monitoring Combination Therapy Trials: New Challenges for the Clinical Laboratory....Pages 11-21 IL-2-Based Consolidative Immunotherapy after Autologous Bone Marrow Transplantation....Pages 23-29 Tumor Immunogenicity Induced by the Local Occurrence of Il-2....Pages 31-37 Thymosin α 1 : Chemistry, Mechanism of Action and Clinical Applications....Pages 39-48 Combination Therapy with Thymosin α1 and Cytokines in the Treatment of Cancer and Infectious Diseases....Pages 49-60 Effect of Thymosin α 1 on Cocaine-Induced Inhibition of T-Cell Dependent Murine Immune Response....Pages 61-66 Regulation of Gene Expression by Interferons....Pages 67-70 Interactions between Tumor Necrosis Factor Alpha and Glucocorticoid Hormones in the Regulation of Tumor Cell Growth in Vitro ....Pages 71-79 Behavioural, Pyrogenic and Electrocortical Effects of Tumor Necrosis Factor - Alpha Given Intracerebrally in Rats....Pages 81-86 Biological Significance and Therapeutic Potential of Tumor-Associated Leukocytes....Pages 87-94 Septic Shock Pathophysiology: Focus on Therapeutic Approach....Pages 95-103 Differentiating Agents and Cancer Therapy. Role of Cellular Lipid Peroxidation and its Product 4-Hydroxynonenal in the Control of Cell Proliferation and Differentiation....Pages 105-114 Inhibition of HIV Replication and Enhancement of Immune Functions by the Acyclic Nucleoside Phosphonate 9-(2-Phosphonyl-Methoxyethyl)Adenine (PMEA)....Pages 115-122 Modulation of Inflammatory Cytokines by a Receptor Antagonist, Autoantibodies, and Fever....Pages 123-134 Cancer Immunochemotherapy: Preliminary Studies with Triazene Compounds....Pages 135-147 Thymosin α1 and α-Inteferon with Cisplatin and Etoposide in Advanced Non-Small-Cell Lung Cancer: A Phase II Study....Pages 149-153 Combination of Chronic Indomethacin and Intermittent IL-2 Therapy in the Treatment of Disseminated Cancer....Pages 155-165 Combination Chemotherapy and Cytokines in the Treatment of Advanced Primary Lung Cancer: Results of a Controlled Clinical Trial....Pages 167-170 Biological Response Modifiers and Differentiating Agents in Myelodisplastic Syndromes....Pages 171-177 Myeloid Growth Factors in Cancer Treatment....Pages 179-187 Efficacy of the Combined Treatment with Fluconazole and Thymosin α 1 Against Candida albicans Infection in Morphine-Treated Mice....Pages 189-194 Anti-Cytokine Therapy of Murine Candidiasis....Pages 195-200 The Basic Research and Clinical Application of Thymopeptidin....Pages 201-208 Treatment of Hepatitis C Virus-Associated Chronic Liver Disease with ß-Interferon and Inosine Pranobex: Combination Schedule vs Monotherapies....Pages 209-215 Sustained Response to Thymosin Therapy in Patients with Chronic Active Hepatitis B....Pages 217-223 Combination Anti-HIV Therapy: Questions and Answers....Pages 225-228 Mechanisms of Disease Progression and CD4 Depletion in HIV-1 Infection....Pages 229-233 Combined Therapy with Zidovudine, Thymosin α1 and α-Interferon in the Treatment of HIV-Infected Patients....Pages 235-242 The Problem of Interferon Species Appearing in Patients with Autoimmune Diseases....Pages 243-249 Back Matter....Pages 251-256 Mechanism of Action and Rationale for the Use of Biological Response Modifiers, Differentiating Agents and Nucleoside Analogues in Combination: Cytokine Synergy in Immunotherapy (J.W. Hadden et al.). Monitoring Combination Therapy Trials (J.L. Rossio et al.). Combination Chemotherapy and BRM Therapy in the Treatment of Cancer: Cancer Immunochemotherapy (G. Graziani et al.). Combination of Chronic Indomethacin and Intermittent IL2 Therapy in the Treatment of Disseminated Cancer (P.K. Lala et al.). Biological Response Modifiers and Differentiating Agents in Myelodisplastic Syndromes